Related Experiment Video
Updated: Mar 7, 2026
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Disaggregation of human islet amyloid polypeptide fibril formation by ruthenium polypyridyl complexes
Dengsen Zhu1, Gehui Gong1, Wenji Wang1
1Department of Chemistry, Renmin University of China, Beijing, China.
Abstract:
The toxicity of amyloid proteins is associated with many degenerative and systematic diseases. The aggregation of human islet amyloid polypeptide may induce pancreatic β-cell death, which is linked to type II diabetes. Ruthenium complexes are inhibitors of various proteins and potential anticancer metallodrugs, which can also be used to disaggregate amyloid proteins. This work reported that several ruthenium polypyridyl complexes remarkably affected the peptide aggregation by predominant hydrophobic interaction and metal coordination, as reflected by thermodynamic parameters and mass spectrometry analysis. Morphology and particle size analysis showed that the amyloid fibrils were disaggregated from long fibrils into small nano particles. Addition of these complexes also decreased the cytotoxicity induced by the peptide. The results indicated that ruthenium polypyridyl complexes may be potential metallodrugs to treat amyloidosis.
Insights
Ruthenium polypyridyl complexes disaggregate toxic amyloid fibrils, reducing cell death associated with type II diabetes and other degenerative diseases. These complexes show potential as metallodrugs for treating amyloidosis.
Area of Science:
- Biochemistry
- Materials Science
- Pharmacology
Background:
- Amyloid protein aggregation is linked to degenerative diseases like type II diabetes.
- Human islet amyloid polypeptide aggregation can cause pancreatic β-cell death.
- Ruthenium complexes are explored as metallodrugs and protein inhibitors.
Purpose of the Study:
- To investigate the effect of ruthenium polypyridyl complexes on amyloid peptide aggregation.
- To assess the potential of these complexes in disaggregating amyloid fibrils.
- To evaluate the therapeutic potential of ruthenium complexes for amyloidosis.
Main Methods:
- Thermodynamic parameter analysis.
- Mass spectrometry.
- Morphology and particle size analysis.
- Cytotoxicity assays.
Main Results:
- Ruthenium polypyridyl complexes inhibited peptide aggregation via hydrophobic interactions and metal coordination.
- Amyloid fibrils were disaggregated into smaller nanoparticles.
- Complex addition reduced peptide-induced cytotoxicity.
Conclusions:
- Ruthenium polypyridyl complexes effectively disaggregate amyloid fibrils.
- These complexes demonstrate potential as metallodrugs for treating amyloidosis and related conditions.
